aget's disease is named after Sir James Paget, who first described this pathology in 1877 (1) . This disorder consists of a focal alteration of bone remodeling with two main pathological hallmarks: the structural integrity of the bone or its biomechanical efficiency is no longer maintained and progression occurs at an extremely swift and haphazard pace. This process is protracted over time, spreads and translates into weakness, deformity, increased fracture risk and pain in the involved bone segment. The deformity of the affected areas alters weight distribution, with a consequent increased risk of secondary arthritis. The increased volume of affected areas may result in the compression of nerve structures, whenever the skull or the spinal column is involved (Tab. I). The most typical form of this radiculitis impacts the acoustic nerve, with secondary hearing loss. The Paget's bone is much more vascularized than normal bone, thus leading to potential localized pain (2) .
However the disease may be diagnosed in an asymptomatic patient in a blood test that reveals elevated levels of alkaline phosphatase, or in an x-ray. Paget's disease mainly affects the axial skeleton, in particular the lumbar-sacral sector, pelvis, skull, femur and tibia (3) . The presence of a high number of asymptomatic patients has made it difficult to carry out epidemiological studies on this disease. Various data from a combination of multiple studies, including reviews of abdominal x-rays, autopsies, questionnaires and serum alkaline phosphatase tests (4-7), reveal an incidence of around 1-3% in over 50s, and 8% in over 80s, SUMMARY Paget's disease of bone is the most common metabolic bone disease after osteoporosis and affects 2-4% of adults over 55 years of age. Its etiology is only partly understood and includes both genetic and environmental factors. The disease may be asymptomatic and can be uncovered incidentally on x-ray or in biochemical tests performed for another condition. It can also manifest itself with bone pain, deformity, fracture or other complications. Paget's disease is diagnosed by x-rays and in general has very typical radiological features, but occasionally the clinical picture may be unusual and a differential diagnosis of sclerotic or lytic metastases needs to be considered. Plasma total alkaline phosphatase activity is the most clinically useful indicator of disease activity. It is elevated in most untreated patients, but may be within the normal range in patients with monostotic or limited disease. Bisphosphonate therapy is indicated for patients with symptoms and should also be considered in patients with disease sites that suggest a risk of complications, such as long bones, vertebrae or base of the skull. Orthopedic surgery in Paget's disease patients includes almost exclusively the correction of fractures and arthroplasty. at least in some countries (8) . The geographic distribution is definitely peculiar, because this pathology is extremely rare in the non-Caucasian population, while among Caucasians it is mostly widespread in England. A few studies have also reported a higher incidence of this disease in rural areas, and in particular in subjects who have frequent contacts with animals (9) . Prevalence increases exponentially with age, approaching 30% among over 85 years. The prevalence of Paget's disease in the United Kingdom (UK) has shown a rapid decline and has been recently estimated at 2% among over 55 years (10, 11) . This suggests that environmental factors may play a role in the development of this condition. The incidence in the UK is currently similar to that of Caucasian populations in other countries. In Italy, a recent prevalence study (12) has been conducted in the cities of Turin and Siena on the basis of x-ray, scintigraphy and biochemical tests. Among over 60 years of age, the overall incidence of the disease accounts for just over 1% and is greater among males with no significant differences between the two cities. It has also shown an increase with age (from 0.7% to 2.4% over several decades), but no significant differences compared to previous studies conducted in Italy. An unexpected greater severity of the disease has been observed both in the sporadic and familial forms in the Campania region (13) . (15) . Subsequently investigators have highlighted that the same mutation is often present on a conserved haplotype, which is consistent with a stable genetic change occurred in the affected population (16) . This observation of a founder effect perfectly matches the epidemiology of Paget's disease (17) , but only in the case of the SQSTM1 mutation. In Europe, Australia, and the United States, comparable rates of SQSTM1 mutation have been reported in or around the ubiquitin-associated domain. There are several specific mutations, the most common of which is, a prolineto-leucine substitution at aminoacid 392 (P392L). Scientists have tried to correlate the severity of the disease with the genotype, but the results have been inconsistent (18) (19) (20) (21) . Attention was therefore shifted to the role of p62 (a product of the SQSTM1 gene) in signaling osteoclast activation via the nuclear factor kappa B. Since this initial discovery, polymorphisms in the genes affecting osteoclast maturation, activation, and fusion pathways have shown to predispose to Paget's disease. Examples (22) : -TNFRSF11A, which codes for the receptor activator of nuclear factor (RANK) kappa B; -TNFRSF11B, which codes for osteoprotegerin; -CSF1, which codes for the macrophage colony-stimulating factor 1; -OPTN, which codes for optineurin, a member of the nuclear factor kappa B modulating protein family. Although there is some evidence that measles and canine distemper viruses can infect osteoclasts and modify their phenotype, there is not enough evidence confirming that these infections by themselves can cause Paget's disease (23) (24) (25) . Multiple epidemiologic studies from around the world have failed to identify conclusively any triggering environmental factors that can actually predispose to Paget's disease, although many have been proposed, such as a rural setting, trauma, infection, and milk ingestion (26) (27) (28) . It is also possible that some local changes resulting from bone and marrow aging may favor the development of this disease. In fact the main risk factor for Paget's disease is perhaps aging, followed by family history. To date genetics cannot fully account for the development of this disease, since there are cases of individuals with SQSTM1 mutations who have no clinical symptoms, not even at an older age, and patients with Paget's disease who have no SQSTM1 mutation (20, 29) .
n COMPLICATIONS Paget's disease is the second most common disorder of the aging bone after osteoporosis. However, unlike osteoporosis, which presents as a systemic fragility of bone, the clinical manifestations of Paget's disease depend on which bones are affected and how enlarged or misshapen they have become.
Common complications
As a consequence of the abnormal bone remodeling, many patients present with bone pain. Bone deformity, headache, and hearing loss may frequently occur, as well as fractures and nerve compression syndromes (such as spinal stenosis, sciatica, cauda equina syndrome). The pagetic bone may not necessarily be the source of pain, which instead could be caused by degenerative changes at affected sites (30, 31) .
Metabolic complications
Metabolic complications are rare today, but they can occur in elderly patients who have an active polyostotic (multibone) disease (32) . The accelerated rate of bone remodeling and the increased vascularity of the pagetic bone have been reported to cause highoutput heart failure. In theory, treatment should aim at slowing down the blood flow in the pagetic bone and restoring the bone turnover to more normal levels (33) . Hypercalcemia can occur, when patients with Paget's disease are immobilized for any reason. Also a higher incidence of kidney stones has been identified in these patients (34, 35).
Osteosarcoma
Osteosarcoma rarely arises in the pagetic bone. Yet Paget's disease may account for a significant number of cases of this cancer in the elderly (36) . In these cases, osteosarcoma is expected to derive from a second genetic mutation, therefore it can be distinguished from the form occurring in young patients and is poorly responsive to treatment (37) . In Scandinavia and Japan, where Paget's disease is rare, the second peak of age-correlated osteosarcoma shows the same mutation (38, 39) . This cancer presents with pain, soft-tissue swelling, and variable elevations in serum alkaline phosphatase. Investigations to date suggest that pagetic lesions and osteosarcomas arising in pagetic bone are probably both caused to some extent by an overexpression of the RANK ligand by stromal cells and may not be related to an inherent defect of osteoclasts (40) .
Giant-cell bone tumors
Giant-cell tumors are also rare, but they can arise in the pagetic bone. A cluster of cases was reported in Avellino and other towns of southern Italy (13) . Furthermore the lesions occur in older individuals and in different sites compared to those seen in the benign giant-cell tumors affecting patients without Paget's disease.
Metastases
Typical bone metastases associated with lymphomas, prostate cancer, and breast cancer hardly ever occur in pagetic sites (41) . A recent case study has noted that patients with prostate cancer and Paget's disease had a later onset of metastasis in the bone than patients without concomitant Paget's disease (42) . The assessment of a patient with Paget's disease requires a comprehensive understanding of potential musculoskeletal consequences at an older age. Pain in Paget's disease is often multifactorial. In the elderly, all causes need to be considered, including end-stage degenerative diseases of the spine, hip, and knees, mechanical instability, compression fractures of the spine, and neuropathies. Therefore, a thorough clinical evaluation is required to plan an adequate treatment strategy. 
n IMAGING
A plain radiography of the affected bones outlines the anatomy of the problem and gives some insights into the cause of pain. Computed tomography or magnetic resonance imaging may prove useful in cases of spinal stenosis, cauda equina syndrome, compression fractures, or suspected malignancy, but they are expensive and not always necessary.
Radiographic features
Paget's disease is presumably a disease of the osteoclast, and the earliest visible lesions are described as lytic. Nevertheless it is unusual to see a purely lytic lesion, which can only be found in the skull (osteoporosis circumscripta), the femur or the tibia with an advancing edge of pure osteolysis. It more often manifests itself with areas of resorption by osteoclasts and areas of bone formation by osteoblasts, thus reflecting the combination of both processes in this disease. Radiographic findings on plain films are usually conclusive, when they show an enlargement of the affected bone, deformity, coarsened trabeculae, and thickened cortices with tunneling (43) . In weight-bearing bones, pseudo-fractures may appear on the convex surface. These bone incongruities may persist for years, heralding fracture only when there is focal pain (44) .
Bone scintigraphy
It is more sensitive than plain radiology in detecting pagetic lesions, and is mainly indicated in newly diagnosed patients to determine the distribution of the disease. It makes it possible to identify the involved bones (important at baseline) with potential complications, depending on the sites, such as the skull base, the spine and long bones.
Biopsy
If such diagnostic findings are not present on the x-ray, then bone biopsy is indicated. In the United States and Canada, where Paget's disease is fairly common, biopsy is rarely used and generally reserved for cases in which the differential diagnosis may point to a potential bone cancer or when the cortex is not visible, the lesions have an unusual pattern or location, or there is a single sclerotic vertebral body (45) . Another indication for biopsy is a new pagetic lesion. For unknown reasons, the pattern of skeletal involvement in Paget's disease tends to be stable throughout the life of the patient. This is another reason why a baseline skeletal scintigraphy (or alternatively a bone scan) is required.
n BIOCHEMICAL MARKERS
A serum alkaline phosphatase (ALP) screening test is usually sufficient to measure bone turnover. Alkaline phosphatase is produced by osteoblasts and is a marker of bone formation, despite its limited accuracy. It is often elevated in active Paget's disease (46), but many patients may have normal serum ALP levels, particularly if they have the monostotic (single-bone) disease. The measurement of other bone formation markers, such as bone-specific alkaline phosphatase, osteocalcin, and procollagen type I peptides, and of bone resorption markers, including the pyridinolines, hydroxyproline, and cross-linked collagens, do not offer any additional information to the serum ALP level (47, 48) . Therefore, since the ALP test is rather inexpensive, available, and reliable, it should be considered the marker of choice in combination with the assessment of liver function by gamma-glutamyl transpeptidate or 5´nu-cleotidase test to exclude that its increase is to be associated with the liver rather than the bone (49) . (2) 
Pamidronate
Pamidronate was initially utilized in an oral formulation (56) (57) (58) (59) , which proved to be poorly tolerated. The drug's availability in the intravenous form for the treatment of malignant bone complications has led to a variety of regimens (60) (61) (62) (63) (64) (65) (66) (67) (68) . The most-utilized protocol (off label in most countries) (82) . A biohumoral improvement has been associated with an improvement of the symptoms and the radiological picture. After these studies, Risedronate has been approved in Italy for Paget's disease treatment, but it has never been included in the national reimbursement drug list.
Clodronate
Clodronate is a first-generation bisphosphonate approved in Italy for the treatment of osteoporosis and malignant bone complications, but not for the treatment of Paget's disease. However clodronate has been the most widely used drug off label for this disease in recent years in Italy. The drug has been the object of a few spontaneous studies (83) (84) (85) (86) . The most frequently used dosage is 300 mg in 500 cc of saline solution for 5-12 days depending on the severity of the disease. This dosage leads approximately to a 50-70% reduction in ALP.
Alendronate
Alendronate at a dosage of 40 mg/die for 6 months has proven efficacious in reducing disease activity and improving the radiographic picture both in studies comparing it against etidronate and in non-controlled studies (87) (88) (89) (90) . Alendronate is not available in Italy in the formulation approved for the treatment of Paget's disease.
Ibandronate
Ibandronate has been studied at a dosage of 2 mg (single infusion) to be repeated if necessary at higher doses in case of failure or rapid relapse (91) . This drug is not approved for the treatment of Paget's disease, but it is available on the Italian market.
Olpadronate
Olpadronate (chemically very similar to pamidronate) is only available in some countries and has been the object of some non-approval-oriented studies. It has yielded similar results to pamidronate (92, 93 (94), including one phase 2 study (95) , which has reported a dose-effect curve that remains linear up to a maximum dosage of 100 mg x 2 intravenously.
Zoledronate
Zoledronate is a nitrogen-containing bisphosphonate. It is administered as a single infusion over 15 min. A re-treatment is often unnecessary for years. In 2005 a randomized clinical trial has demonstrated the efficacy of zoledronic acid 5 mg intravenously compared with oral risedronate for the treatment of Paget's disease (96) . In observational extension studies which lasted for as long as 6.5 years, zoledronic acid has shown to be superior to risedronate in terms of number of patients experiencing a sustained clinical remission (97) . Although there are currently many bisphosphonates available on the market, a single infusion of 5 mg of zoledronic acid seems an ideal treatment at least in patients who have a contraindication or an aversion to intravenous therapy. This drug tends to normalize the serum ALP level quickly over the long term, also in patients who have used other bisphosphonates in the past or has become resistant to them. This has led to the approval of a dose of zoledronate 5 mg (Aclasta) for the treatment of Paget's disease by both the FDA and the European Medicines Evaluation Agency (EMEA).
Bisphosphonates reduce bone turnover but do not correct deformities
In randomized clinical trials, bisphosphonates have shown to restore bone remodeling to more normal levels, relieve bone pain, lower the serum ALP level and heal radiographically-visible lesions, but they have not been able to prevent the progression of deformity or restore the structural integrity of the bone.
A study named Paget's Disease: Randomized Trial of Intensive Versus Symptomatic Management (PRISM) conducted on a sample of 1324 patients with Paget's disease in the United Kingdom has shown no difference in the incidence of fracture, orthopedic surgery, quality of life, or hearing loss. This study has foreseen a follow up at 2 and 5 years and has compared bisphosphonate treatment versus symptomatic management. However a statistically significant difference has been detected in serum ALP between the two groups (P<0.001) (98) . In an observational extension study of zoledronic acid (97) ¾ of fractures occurred in the group treated with zoledronic acid, thus confirming the findings of the PRISM study.
n CALCITONIN Calcitonin can still be useful in easing pain in Paget's disease, healing bone lesions, and reducing the metabolic activity of the pagetic bone in patients who cannot receive bisphosphonates. It is administered by injection at doses of 50 to 100 IU daily or every other day. Although it may not offer a protracted clinical remission, it remains a safe, well-tolerated, and well-studied drug for the treatment of Paget's disease and is approved for this indication (99, 100) .
n DENOSUMAB This drug has not been formally studied in Paget's disease, but recent case reports have shown it can be effective in patients affected by this disease (101) . n MONITORING OF SPECIFIC DRUG TREATMENT
The management of Paget's disease is depicted in Table III . The goal of Paget's disease treatment must be the regression of symptoms along with the improvement of the radiological picture. However, as most patients begin treatment when the disease is at an advanced stage, prevention of complications becomes the main priority. For this purpose it is necessary to keep the disease in a state of remission or limited activity, therefore therapeutic monitoring must be based on bone turnover assessment. With regards in particular to fast-acting drugs, bone re-absorption markers decrease significantly within just a few days. Total ALP is the most widely utilized bone turnover marker in the clinical practice, as its levels correlate well with the extent and activity of the disease, and also has a very good variation coefficient (<10%). The level of the bone specific enzyme is certainly more accurate for patients with a concomitant liver disease, and is probably also more sensitive in cases of limited monostotic Paget's disease. A follow-up scintigraphy is almost never justified, both because it offers no substantial advantages over ALP measurement and it involves exposure to radiation. A second bone scintigraphy may be useful to check the evolution of the disease with a small monostotic symptomatic lesion and normal ALP levels. In the monitoring of bisphosphonate therapy, the following items should be kept into account (2): 1) When utilizing total or bone ALP for monitoring purposes, it should be remembered that the nadir is reached after no less than 6 months from the beginning of treatment. An ALP measurement prior to 6 months is not justified, as it cannot provide any indication as to the efficacy of the treatment cycle.
2) The drop in ALP after re-treatment with bisphosphonates is almost always lower to that attained during the first treatment cycle. 3) There are forms of Paget's disease that are extremely limited or localized in critical areas (peri-articular areas, skull, vertebrae) and therefore symptomatic which may be associated with normal ALP levels. In these cases, the re-treatment threshold may be identified within the normal range based on some individualized clinical criteria. 4) There is data, recently supported by the follow-up results Zoledronate study (97) , which confirms that the complete normalization of ALP in subjects with moderate-severe forms of Paget's is associated with a very long-term, possibly permanent, suppression of the disease, thus leading to a clinical picture with inactive disease. Such outcome is occasionally found in very elderly subjects, whose only indication of the prior disease is the persistence of radiographically visible lesions. 5) Indications for re-treatment. There is no consensus regarding a definition of relapse requiring a new cycle of treatment. An increase in ALP after it reaches its nadir at 6 months after the beginning of treatment is physiological, even when normalization of bone turnover has not been attained. In fact, it should be remembered that intensive and protracted cycles of treatment bring about a suppression of the turnover even of normal bone tissue, which may contribute to classify incorrectly a patient with small lesions as being in complete remission. A few months after the treatment cycle, there are inevitably signs of a gradual restoration of the turnover of the nonpagetic bone. However, a reactivation of the disease may be considered only when this increase exceeds 25%. In the case of acquired resistance to a drug, i.e. when at 6 months from the administration of treatment, suppression of ALP is below 50% of baseline values, it is useful to switch to another bisphosphonate (108, 109). 6) Young subjects. The detection of pagetic lesions in young subjects, especially females, may raise uncertainties with regard to possible teratogenous risks or long-term safety. The almost inevitable evolution of the disease over the years requires an adequate medical treatment. Although experimental studies seem to exclude any teratogenicity of the bisphosphonates, it is reasonable to advise postponing a pregnancy for a few months after a treatment cycle with bisphosphonates. 
